Replimune looks to rope in $225M on the back of melanoma da­ta

The Mass­a­chu­setts-based, on­colyt­ic virus biotech Replimune is feel­ing bull­ish now that it has lift­ed the cov­er on da­ta for its lead prod­uct.

Replimune said Thurs­day it looks to nab about $225 mil­lion from a pub­lic of­fer­ing af­ter giv­ing a snap­shot of some ini­tial da­ta from its IGNYTE clin­i­cal study ear­li­er this week. The tri­al is in­ves­ti­gat­ing RP1 in com­bi­na­tion with Op­di­vo, for pa­tients with melanoma and who did not have a re­sponse when be­ing treat­ed with a PD-1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER